Corante

About this Author
Derek Lowe
Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: derekb.lowe@gmail.com Twitter: Dereklowe

Chemistry and Pharma Blogs:
The Science Business
Org Prep Daily
Kilomentor
On Pharma
Kinase Pro
Chemical Quantum Images
The LouRoe
One in Ten Thousand
Periodic Tabloid
Chemical Musings
C&E News Blog
Chemiotics II
Noel O'Blog
In Vivo Blog
Chirality
BBSRC/Douglas Kell
Drug Discovery Opinion
The Chemblog
Realizations in Biostatistics
Heterocyclic Chemistry Blog
Molecule of the Day
Chemjobber
WSJ Health Blog
PK/PD
Social Detritus
ChemSpider Blog
Node in the Noosphere
Pharmagossip
Organometallic Current
Useful Chemistry
Great Molecular Crapshoot
No Name No Slogan
Post Doc Ergo Propter Doc
SimBioSys
Culture of Chemistry
The Curious Wavefunction
Chemical Sabbatical
Totally Synthetic
Molecular Philosophy
Zusammen
Pharma's Cutting Edge
My Chemical Journey
The F- Blog
Chemical Professionals
Generally Chemistry
Chemistry World Blog
Eigenfunction/Eigenvalue
Synthesizing Ideas
Carbon-Based Curiosities
Business|Bytes|Genes|Molecules
Eye on FDA
Sigma-Aldrich ChemBlogs
Peter Murray-Rust
Chemical Forums
Depth-First
Curly Arrow
ChemCafe
Power of Goo
Fetz the Chemist
Carbon Tet
Chemical Crosspatch
Sceptical Chymist
Atomchuxky
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa
Making Graphite Work
Realm of Organic Synthesis
Liquid Carbon
Pharma Blog Review


Science Blogs and News:
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Life of a Lab Rat
Nobel Intent
SciTech Daily
Is This Thing On?
Science Blog
Eastern Blot
FuturePundit
Flags and Lollipops
Aetiology
Gene Expression (I)
Gene Expression (II)
Sciencebase
Pharyngula
Adventures in Ethics and Science
Terra Sigillata
Transterrestrial Musings
Slashdot Science
A Scientist's Life
Living the Scientific Life
Humans in Science
Speculist
Science, Shrimp and Grits
Cosmic Variance
The Capsule
Zeroth Order Approximation
Science Library Blog
Biology News Net


Medical Blogs
Med Tech Sentinel
DB's Medical Rants
Science-Based Medicine
GruntDoc
The Health Care Blog
Respectful Insolence
Black Triangle
Diabetes Mine


Economics and Business
Marginal Revolution
Arnold Kling
The Volokh Conspiracy
Knowledge Problem
The Stalwart


Politics / Current Events
Virginia Postrel
Tinkerty Tonk
Instapundit
Megan McArdle
Mickey Kaus
Colby Cosh
Alien Corn
No Watermelons


Belles Lettres
Two Blowhards
Critical Mass
Arts and Letters Daily
God of the Machine
Armavirumque
About Last Night
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« Part Nine Hundred and Forty Two in a Series. . . | Main | Pyrotechnic Days »

June 29, 2006

Rimonabant Arrives

Email This Entry

Posted by Derek

Well, although Sanofi-Aventis still hasn't been very forthcoming on their FDA problems, their CB-1 antagonist Accomplia (rimonabant) has now been approved in Europe, and is already on sale in the UK. (S-A still say that they expect it to make it through in the US by the end of the year).

This article from Bloomberg is an excellent summary of the situation. No new obesity drugs have been approved for almost ten years, and potential sales of a safe and effective one are almost impossible to estimate. But there's room to argue about how effective rimonabant is, and (as with any drug) there's always room to argue about safety. And that's particularly true in what some people are already calling the post-Vioxx era.

The article makes some of the same points that I've made here before: new therapies and new mechanisms have risks, and there is no way that we (the drug industry and the regulatory authorities) can get rid of them. We can test for the big ones and read the signs for the smaller ones, but if a new drug is going to taken by millions of people for long periods, things will happen that no one ever saw during the clinical trials.

I hope, for Sanofi's sake and everyone else's, that there's nothing weird lurking down in the statistical weeds this time. But you can be absolutely sure that the company is holding its breath. We all do. It doesn't help.

Comments (12) + TrackBacks (0) | Category: Diabetes and Obesity


COMMENTS

1. Speedy on June 30, 2006 12:52 PM writes...

Derek, would you mind expanding on the effectiveness and risks of these various "diet drugs" vs. plain old amphetamine?

Permalink to Comment

2. Luke, I am your fungus! on June 30, 2006 2:12 PM writes...

Risk vs effectiveness: Smoking Rimonabant can be fateful...

Permalink to Comment

3. Joe Guy on June 30, 2006 2:58 PM writes...

Or....

How about expanding upon olde timey pharmacology ala Albert Hoffman or those that "discovered" amphetamines.

Used to be the pharmacologist was his own subject, not the rat. Guess they dont teach those methods anymore in school!

Permalink to Comment

4. Speedy on June 30, 2006 6:30 PM writes...

Haha Joe. Now, seriously, whats in the pipeline that will work better than dexadrine+tricor, or is that combo the best that can be done?

Permalink to Comment

5. Handles on June 30, 2006 8:39 PM writes...

The old post about CB-1 agonists and neuroprotection was interesting. More on the same at the BBC:
http://news.bbc.co.uk/2/hi/uk_news/england/devon/5130472.stm

Permalink to Comment

6. Donny on July 1, 2006 8:09 AM writes...

I've been studying rimonabant for several years now as part of my work as a pharma industry market analyst.

The dollar potential of the obesity market is staggering. Take just the US, for example:
1/3 of the population is overweight
1/3 of the population is obese
that's 200 million potential patients.

If we assume that just 1% of this patient population will try rimonabant for 6 months (about the average amount of time that patients tried Xenical and Meridia), that's 2 million patients X 180 days of treatment X $3 per day of treatment = $1 billion in US sales of rimonabant in 6 months...that's blockbuster status.

And there are estimates out there that $30 billion plus dollars are spent in the US alone each year on weight loss products and services (diet foods, diet groups, OTC drugs, gyms, gastric bypass procedures, etc.)--this tells you what the potential can be for a safe and effective means of causing weight loss.

Of course this is an oversimplification, and the real picture is much more complicated. You have to factor in reimbursement (will HMO's pay for something they still consider to be a lifestyle issue rather than a medical issue?), the willingness of physicians to prescribe a new drug with a novel mechanism of action (most prefer to wait and see until some time has passed and the safety and efficacy is better known; this is doubly true in the years post-PhenFen and Vioxx), how hungry patient demand will be, whether metabolic syndrome will become more formally recognized as a disease entity, etc.

However, other weight loss drugs over the years have received a lot of hype too, and they have not done well in the marketplace, because they had only modest efficacy, not so good side effect profiles, were expensive, and were not reimbursed. Rimonabant improves upon the safety and efficacy profiles of existing obesity drugs only modestly, and it remains to be seen whether the market will reward these modest improvements.

Permalink to Comment

7. Polly on July 19, 2006 10:13 PM writes...

I've been waiting for this drug to get through the FDA. Been 'fat' all my 56 years but lost 87 lbs on Phen/Fen and never felt better. Not a thing happened to me and I still struggle to keep it off.

The problem with EVERY drug is if the word 'DIET' is attached to it - the little blonde bimbo's of the world will have the media all over it.

Then, we're all fat lazy slobs and they find someone who has a reaction to the drug and all bets are off!

Like no one ever died from being allergic to penicillin??

We're all grown ups; we should be allowed to make our own decisions!!!

Thanks for listening.

Permalink to Comment

8. BKay on July 23, 2006 2:47 PM writes...

I have just joined a double blind rimonabant study. So far I am not positive at this point that I am taking the drug but having some mild symptoms that I don't usually have. Not ready to jump to any conclusions. This is a new study (USA) that began recently. It was recommended to me by my physician for metabolic syndrome type sxs. I am at high risk. I am not obese but some overweight. Most might not even consider me overweight but I am enough to increase my risk due to inherited factors. I am hoping to lose some weight, decrease cholesterol, lower blood pressure, increase good cholesteral and other touted benefits. We shall see.

Permalink to Comment

9. mairead on August 15, 2006 11:57 AM writes...

My doctor won't prescribe any diet pill, so can someone tell me how do I find a doctor who will. I live in Palm Desert., California. I have been told that buying it on the net is not a good idea since the reliability is not guaranteed.

Permalink to Comment

10. mairead on August 15, 2006 11:57 AM writes...

My doctor won't prescribe any diet pill, so can someone tell me how do I find a doctor who will. I live in Palm Desert., California. I have been told that buying it on the net is not a good idea since the reliability is not guaranteed.

Permalink to Comment

11. Judy on June 22, 2007 7:05 PM writes...

I AM PARTICPATING IN A TRIAL FOR THIS DRUG THRU dESERT MEDICAL CLINICAL RESEARCH..I'M NOT SURE IF THE STUDY IS CLOSED- LENGTH IS 3 YRS INCLUDES THE TRIAL DRUG, MEDICAL MONITORING & TESTING IF YOU QUALIFY. SOUNDS LIKE YOU WOULD. GIVE THEM A CALL.

Permalink to Comment

12. IamUsuallyWright on July 6, 2008 2:29 PM writes...

There is certainly some unknown risks with any drug, and with Rimonabant the know risks are not negligable. However, those risks must always be weighed against the potential benefit of the drug.

Just as an aside, Rimonabant works very well in combination with other drugs since you don't have to worry about anything else having much effect on CB1 receptors.

Permalink to Comment

POST A COMMENT




Remember Me?



EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
Dealing With Hedgehog Screening Results
Animal Rights, You Say?
Blogroll Update
Pharma's Return on Investment: Yikes
How A Real Drug Industry Project Meeting Goes
Ghostwriting
Just Give It to NIH
How Not To Do It: The Secret Patent Decoder Ring